Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Gink­go inks $144M deal with Mer­ck to en­gi­neer en­zymes to im­prove in­gre­di­ent man­u­fac­tur­ing

While Mer­ck has not been averse to part­ner­ing with small­er com­pa­nies and the odd start­up, its lat­est part­ner­ship sees it link­ing arms with Gink­go Bioworks to help boost ac­tive phar­ma­ceu­ti­cal in­gre­di­ent pro­duc­tion through the use of en­zymes.

The part­ner­ship will have Gink­go de­vel­op a strain of bio­cat­a­lysts that can be used in chem­i­cal syn­the­sis for the pro­duc­tion of APIs. Gink­go can earn up­front R&D fees and mile­stone pay­ments, as well as com­mer­cial pay­ments which have the po­ten­tial to rake in up to $144 mil­lion for the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.